Loading clinical trials...
Loading clinical trials...
This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Masonic Cancer Center, University of Minnesota
NCT03333200 · MLD, Krabbe Disease, and more
NCT07361536 · MPS I, MPS IV A, and more
NCT06149403 · MPS-IH (Hurler Syndrome)
NCT04571970 · Mucopolysaccharidosis Type II (MPS II)
NCT02294877 · Mucopolysaccharidosis IV Type A, Morquio A Syndrome, and more
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions